Literature DB >> 23487023

NK cell CD16 surface expression and function is regulated by a disintegrin and metalloprotease-17 (ADAM17).

Rizwan Romee1, Bree Foley, Todd Lenvik, Yue Wang, Bin Zhang, Dave Ankarlo, Xianghua Luo, Sarah Cooley, Mike Verneris, Bruce Walcheck, Jeffrey Miller.   

Abstract

The Fc receptor CD16 is present on essentially all CD56(dim) peripheral blood natural killer (NK) cells. Upon recognition of antibody-coated cells it delivers a potent signal to NK cells, which eliminate targets through direct killing and cytokine production. Here we investigated the regulation of CD16 surface expression after NK cell activation. Cytokine activation and target cell stimulation led to marked decreases in CD16 expression. Activation of CD56(dim) NK cells by cross-linking CD16 with antibodies resulted in a loss of CD16 and CD62L, which correlated with increased interferon-γ production. A disintegrin and metalloprotease-17 (ADAM17) is shown to be expressed by NK cells, and its selective inhibition abrogated CD16 and CD62L shedding, and led to enhanced interferon-γ production, especially when triggering was delivered through CD16. Fc-induced production of cytokines by NK cells exposed to rituximab-coated B cell targets was also enhanced by ADAM17 inhibition. This supports an important role for targeting ADAM17 to prevent CD16 shedding and improve the efficacy of therapeutic antibodies. Our findings demonstrate that over-activation of ADAM17 in NK cells may be detrimental to their effector functions by down-regulating surface expression of CD16 and CD62L.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23487023      PMCID: PMC3643761          DOI: 10.1182/blood-2012-04-425397

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  50 in total

1.  Differential cytokine and chemokine gene expression by human NK cells following activation with IL-18 or IL-15 in combination with IL-12: implications for the innate immune response.

Authors:  T A Fehniger; M H Shah; M J Turner; J B VanDeusen; S P Whitman; M A Cooper; K Suzuki; M Wechser; F Goodsaid; M A Caligiuri
Journal:  J Immunol       Date:  1999-04-15       Impact factor: 5.422

2.  Natural killer cell signaling pathways.

Authors:  Eric Vivier; Jacques A Nunès; Frédéric Vély
Journal:  Science       Date:  2004-11-26       Impact factor: 47.728

Review 3.  Self-tolerance of natural killer cells.

Authors:  David H Raulet; Russell E Vance
Journal:  Nat Rev Immunol       Date:  2006-07       Impact factor: 53.106

4.  The strength of inhibitory input during education quantitatively tunes the functional responsiveness of individual natural killer cells.

Authors:  Petter Brodin; Tadepally Lakshmikanth; Sofia Johansson; Klas Kärre; Petter Höglund
Journal:  Blood       Date:  2008-10-30       Impact factor: 22.113

Review 5.  The roles of IFN gamma in protection against tumor development and cancer immunoediting.

Authors:  Hiroaki Ikeda; Lloyd J Old; Robert D Schreiber
Journal:  Cytokine Growth Factor Rev       Date:  2002-04       Impact factor: 7.638

6.  ADAM17 deficiency by mature neutrophils has differential effects on L-selectin shedding.

Authors:  Ying Li; Jennifer Brazzell; Amy Herrera; Bruce Walcheck
Journal:  Blood       Date:  2006-05-30       Impact factor: 22.113

7.  ADAM17 cleaves CD16b (FcγRIIIb) in human neutrophils.

Authors:  Yue Wang; Jianming Wu; Robert Newton; Nooshin S Bahaie; Chunmei Long; Bruce Walcheck
Journal:  Biochim Biophys Acta       Date:  2012-12-08

8.  Tissue-specific homing and expansion of donor NK cells in allogeneic bone marrow transplantation.

Authors:  Janelle A Olson; Robert Zeiser; Andreas Beilhack; Joshua J Goldman; Robert S Negrin
Journal:  J Immunol       Date:  2009-08-05       Impact factor: 5.422

9.  NK cell responsiveness is tuned commensurate with the number of inhibitory receptors for self-MHC class I: the rheostat model.

Authors:  Nathalie T Joncker; Nadine C Fernandez; Emmanuel Treiner; Eric Vivier; David H Raulet
Journal:  J Immunol       Date:  2009-04-15       Impact factor: 5.422

10.  Matrix metalloprotease inhibitors restore impaired NK cell-mediated antibody-dependent cellular cytotoxicity in human immunodeficiency virus type 1 infection.

Authors:  Qingquan Liu; Yongtao Sun; Suzannah Rihn; Anne Nolting; Peter Nicholas Tsoukas; Stephanie Jost; Kristen Cohen; Bruce Walker; Galit Alter
Journal:  J Virol       Date:  2009-06-24       Impact factor: 5.103

View more
  203 in total

1.  ADAM17 and CD56low CD16low NK cells.

Authors:  Rizwan Romee; Jeffrey S Miller
Journal:  Haematologica       Date:  2015-08       Impact factor: 9.941

Review 2.  Beyond Viral Neutralization.

Authors:  George K Lewis; Marzena Pazgier; David T Evans; Guido Ferrari; Stylianos Bournazos; Matthew S Parsons; Nicole F Bernard; Andrés Finzi
Journal:  AIDS Res Hum Retroviruses       Date:  2017-02-16       Impact factor: 2.205

3.  Response to comment on Multifunctional human CD56low CD16low NK cells are the prominent subset in bone marrow of both pediatric healthy donors and leukemic patients.

Authors:  Helena Stabile; Paolo Nisti; Daria Pagliara; Franco Locatelli; Angela Santoni; Angela Gismondi
Journal:  Haematologica       Date:  2015-08       Impact factor: 9.941

Review 4.  Cellular pathways in the development of human and murine innate lymphoid cells.

Authors:  Steven D Scoville; Aharon G Freud; Michael A Caligiuri
Journal:  Curr Opin Immunol       Date:  2018-12-19       Impact factor: 7.486

5.  Phenotypical and functional profiles of natural killer cells exhibiting matrix metalloproteinase-mediated CD16 cleavage after anti-HIV antibody-dependent activation.

Authors:  C-C Tang; G Isitman; J Bruneau; C Tremblay; N F Bernard; S J Kent; M S Parsons
Journal:  Clin Exp Immunol       Date:  2015-06-07       Impact factor: 4.330

6.  FcγRIIIa-dependent IFN-γ release in whole blood assay is predictive of therapeutic IgG1 antibodies safety.

Authors:  Nada S Alakhras; Jiabin Qiu; Guilherme V Rocha; Derrick R Witcher; Anja Koester; Jinsam You; David A Schaer; Rikke B Holmgaard; Kyla Driscoll; Jeffrey A Willy; Laurent P Malherbe
Journal:  MAbs       Date:  2018-07-26       Impact factor: 5.857

7.  The Fc Domain of Immunoglobulin Is Sufficient to Bridge NK Cells with Virally Infected Cells.

Authors:  Hong-Sheng Dai; Nathaniel Griffin; Chelsea Bolyard; Hsiaoyin Charlene Mao; Jianying Zhang; Timothy P Cripe; Tadahiro Suenaga; Hisashi Arase; Ichiro Nakano; E A Chiocca; Balveen Kaur; Jianhua Yu; Michael A Caligiuri
Journal:  Immunity       Date:  2017-07-18       Impact factor: 31.745

8.  Expansion and homing of adoptively transferred human natural killer cells in immunodeficient mice varies with product preparation and in vivo cytokine administration: implications for clinical therapy.

Authors:  Jeffrey S Miller; Cliona M Rooney; Julie Curtsinger; Ron McElmurry; Valarie McCullar; Michael R Verneris; Natalia Lapteva; David McKenna; John E Wagner; Bruce R Blazar; Jakub Tolar
Journal:  Biol Blood Marrow Transplant       Date:  2014-05-09       Impact factor: 5.742

Review 9.  Exploring the NK cell platform for cancer immunotherapy.

Authors:  Jacob A Myers; Jeffrey S Miller
Journal:  Nat Rev Clin Oncol       Date:  2020-09-15       Impact factor: 66.675

10.  CD16xCD33 bispecific killer cell engager (BiKE) activates NK cells against primary MDS and MDSC CD33+ targets.

Authors:  Michelle K Gleason; Julie A Ross; Erica D Warlick; Troy C Lund; Michael R Verneris; Andres Wiernik; Stephen Spellman; Michael D Haagenson; Alexander J Lenvik; Mark R Litzow; Pearlie K Epling-Burnette; Bruce R Blazar; Louis M Weiner; Daniel J Weisdorf; Daniel A Vallera; Jeffrey S Miller
Journal:  Blood       Date:  2014-03-20       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.